Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)

BACKGROUND: PF-06439535 (bevacizumab-bvzr; Zirabev(®)) is a biosimilar of bevacizumab reference product (RP; Avastin(®)). This study describes the formulation development for PF-06439535. METHODS: PF-06439535 was formulated in several buffers and stored for 12 weeks at 40 °C to determine the optimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingram, Rebecca L., Weiser, Sarah E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985529/
https://www.ncbi.nlm.nih.gov/pubmed/36811761
http://dx.doi.org/10.1007/s40268-023-00411-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985529/
https://www.ncbi.nlm.nih.gov/pubmed/36811761
http://dx.doi.org/10.1007/s40268-023-00411-z

Ejemplares similares